Retina/Vitreous News

Luxturna maintained long-term improvements in ambulatory vision, light sensitivity and visual field in patients with biallelic RPE65 mutation-associated retinal diseases, according to a study.

In this Healio Video Perspective from the ASRS meeting, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration.

In this Healio Video Perspective from the ASRS meeting, Danny Mammo, MD, of Cole Eye Institute discusses the real-world effect of triamcinolone acetonide on IOP in patients with uveitic macular edema.

One intravitreal injection of 4D-150 helped reduce the mean annualized anti-VEGF injection rate in patients with wet age-related macular degeneration, according to a study presented at the American Society of Retina Specialists meeting.

In this Healio Video Perspective from the ASRS meeting, Durga Borkar, MD, of Duke University Eye Center presents data from a phase 1b study investigating ONL1204, a Fas inhibitor, for geographic atrophy.

Interim safety data from a post-authorization study of Luxturna in patients with genetic retinal diseases were consistent with clinical trial data, according to a presentation at the American Society of Retina Specialists annual meeting.

Taking a daily supplement with antioxidant vitamins and minerals may slow the progression of late-stage dry age-related macular degeneration and could help maintain central vision in affected patients, according to researchers at NIH.

In this Healio Video Perspective from the ASRS meeting, Margaret Chang, MD, MS, of Retinal Consultants Medical Group presents 2-year results for the port delivery system with ranibizumab.

In this Healio Video Perspective from the ASRS meeting, Laurent Fischer, MD, of Adverum Biotechnologies discusses 26-week results from the phase 2 LUNA study investigating Ixo-vec for neovascular age-related macular degeneration.

PARK CITY, Utah — Outcomes from the phase 1/2a HORNBILL study indicate a potential disease-modifying effect of BI 764524 in eyes with diabetic macular ischemia.